A new study from researchers at Kumamoto University sheds light on a potential link between exposure to certain everyday chemicals during pregnancy and the development of asthma in children. The… read more.
Many studies suggest that an earlier age at menopause is more detrimental to a woman’s health, leading to an increased risk for adverse health conditions such as heart disease, diabetes,… read more.
Positive data from the phase III LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolled chronic spontaneous urticaria (CSU) who receive background… read more.
About 10% of Americans believe they are allergic to penicillin, and approximately 90% of those patients are not actually allergic. As a result, those with the penicillin allergy… read more.
One treatment with a CRISPR-Cas9 based gene editing therapy, NTLA-2002, could replace daily medication of many patients with hereditary angioedema (HAE), a painful condition with severe onset of… read more.
Positive high-level results from the BATURA Phase IIIb trial showed AstraZeneca’s Airsupra (albuterol/budesonide) met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk… read more.
Infants fed exclusively with breast milk during their hospitalization at birth are less likely to develop asthma in early childhood, according to research presented on Sept. 27 at… read more.
Children with asthma who are exposed to high levels of indoor allergens, such as cockroach and mouse allergens, are at an increased risk of developing respiratory viral infections… read more.
Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy, announced that the FDA has approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], for the treatment of toddlers… read more.
ARS Pharmaceuticals, Inc. announced the European Commission’s approval of EURneffy for emergency treatment of severe allergic reactions in adults and children weighing at least 30 kilograms. This approval… read more.
AstraZeneca’s Fasenra (benralizumab) has been approved in China by the country’s National Medical Products Association (NMPA) for the maintenance treatment of patients 12 years of age and older… read more.
ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
